KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Assets (2016 - 2025)

Regeneron Pharmaceuticals has reported Current Assets over the past 17 years, most recently at $18.0 billion for Q4 2025.

  • Quarterly results put Current Assets at $18.0 billion for Q4 2025, down 3.42% from a year ago — trailing twelve months through Dec 2025 was $18.0 billion (down 3.42% YoY), and the annual figure for FY2025 was $18.0 billion, down 3.42%.
  • Current Assets for Q4 2025 was $18.0 billion at Regeneron Pharmaceuticals, roughly flat from $18.0 billion in the prior quarter.
  • Over the last five years, Current Assets for REGN hit a ceiling of $19.5 billion in Q4 2023 and a floor of $10.1 billion in Q1 2021.
  • Median Current Assets over the past 5 years was $16.9 billion (2023), compared with a mean of $16.5 billion.
  • Biggest five-year swings in Current Assets: soared 69.69% in 2021 and later dropped 11.65% in 2025.
  • Regeneron Pharmaceuticals' Current Assets stood at $14.0 billion in 2021, then rose by 13.34% to $15.9 billion in 2022, then increased by 22.63% to $19.5 billion in 2023, then dropped by 4.2% to $18.7 billion in 2024, then fell by 3.42% to $18.0 billion in 2025.
  • The last three reported values for Current Assets were $18.0 billion (Q4 2025), $18.0 billion (Q3 2025), and $16.9 billion (Q2 2025) per Business Quant data.